Seres Therapeutics (MCRB) PT Lowered to $32 at Piper Sandler, Following Clinical Business Update
Tweet
Share
E-mailGet Alerts MCRB Hot Sheet
Price: $4.54 +1.34%
Rating Summary:
9 Buy, 3 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
9 Buy, 3 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $32.00 (from $40.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seres Therapeutics (MCRB) files $300M mixed shelf
- Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
- Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
